Futura Medical - Notice of Interim Results

Futura Medical PLC

18 August 2023

 

18 August 2023

 Futura Medical plc

("Futura" or the "Company")

Notice of Interim Results

Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), the pharmaceutical company developing innovative sexual health products, will announce its interim results for the six months ended 30 June 2023 on Monday 18^th September 2023.

The Company will host a webcast for investors and analysts on the day of the results, which will be made available within the investor centre section of the Company's website.

A Retail Investor event is scheduled for Tuesday 19^th September at 10.00am BST with Investor Meet Company. Retail Investors can register via www.investormeetcompany.com.

-ENDS-

For further information, please contact:

Futura Medical plc

James Barder, Chief Executive Officer

Angela Hildreth, Finance Director and COO

Email: [e-mail]

Tel: [phone]

www.futuramedical.com

Nominated Adviser and Sole Broker:

Liberum

Phil Walker/ Richard Lindley/ Ben Cryer

Tel: [phone]

For media enquiries please contact:

Optimum Strategic Communications

Nick Bastin/ Jonathan Edwards/ Zoe Bolt/ Elena Bates

Email: [e-mail]

Tel: [phone]

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing innovative products based on its proprietary, transdermal DermaSys® technology.

MED3000, the Company's breakthrough treatment for erectile dysfunction ("ED") has a unique evaporative mode of action and is clinically proven as an effective topical treatment for adult men with ED, with a key claim of "Helps you get an erection within 10 minutes". Eroxon® is available Over the Counter ("OTC") without a doctor's prescription. www.eroxon.com.

MED3000 is being manufactured and commercialised under the brand name Eroxon® in regulatory approved countries and is FDA approved in the US, CE marked in Europe and UKCA marked in the UK and a growing number of countries across the world. Futura has commercial agreements with the likes of Haleon for the US market and Cooper Consumer Health for Europe.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com.

 

END